BRCA2 and cancer: NGS using MSK-IMPACT, a hybrid capture-based NGS assay that sequences all exons of 468 cancer-associated genes, revealed an acquired BRCA2 intragenic deletion of exon 11 predicted to excise the germline mutation and restore the BRCA2 reading frame to recreate a functional protein31.